Canadian pharma exports to the U.S. face Section 232 pharma effective July 31, 2026 (branded patented drugs only; generics excluded). Most Canadian pharma – particularly Quebec generics – are excluded. USMCA-qualifying Canadian pharma is exempt from Section 122 plus excluded from Section 232 pharma.
This guide covers Canadian Pharma U.S. Trade Strategy. For SMB importers and exporters, the practical implementation depends on volume, sector, and operational structure.
For background, see /usmca-cusma/ and our complete cross-border practice.
Section 232 pharma scope
Branded patented drugs covered effective July 31. Generics, biosimilars excluded under current proclamation.
Quebec generic manufacturers
Most Quebec generic pharma manufacturers are excluded from Section 232. Section 122 still applies unless USMCA-qualifying.
USMCA pharma qualification
Canadian pharma can qualify under USMCA tariff-shift rules. Active ingredient transformation in Canada supports qualification.
Documentation
Manufacturing process flowcharts, supplier certificates for starting materials, USMCA Certificate of Origin.
Frequently asked questions
When is this most relevant?
For SMB importers/exporters in cross-border operations or those with active sourcing/distribution decisions to make.
What documentation is needed?
CBP Form 7501, supplier certificates, BOM analysis, country-of-origin documentation, USMCA/CUSMA Certificate of Origin where applicable.
Can you handle the full setup?
Yes. End-to-end engagements ranging from $3,500-$15,000 depending on complexity. Ongoing retainer for active operations.
What’s the typical timeline?
Simple cases 2-4 weeks; complex cross-jurisdiction setups 6-12 weeks.
How do I begin?
Book a 15-minute scoping call. We confirm fit and scope before any engagement.
Get started
Book a Canadian cross-border tariff consultation.